At diagnosis, the treatment and the prognosis of PCa are determined by the stratified risk group on the basis of prostate-specific antigen (PSA) level, the sum of Gleason patterns, and the clinical stage. The gene discussed is KLK3; the disease is posterior cortical atrophy.